Abstract 4367655: Comparative Cardiometabolic Outcomes of Tirzepatide Versus Semaglutide in Patients with HFpEF and Obesity: A Real-World Multicenter Cohort Study

赛马鲁肽 医学 内科学 心肌梗塞 危险系数 杜拉鲁肽 急性失代偿性心力衰竭 心力衰竭 队列研究 心脏病学 2型糖尿病 队列 回顾性队列研究 肥胖悖论 不利影响 血糖性 肥胖 胰高血糖素样肽1受体 比例危险模型 超重 糖尿病 倾向得分匹配 四分位间距 减肥
作者
Siddharth Agrawal,Ritu Chandra Prakash Tated,Hritvik Jain,Kriti Soni,Saraschandra Vallabhajosyula,Pragyat Futela
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:152 (Suppl_3)
标识
DOI:10.1161/circ.152.suppl_3.4367655
摘要

Background: HFpEF frequently coexists with obesity and type 2 diabetes, both of which are associated with adverse cardiometabolic outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide have shown promise in weight and glycemic control, while tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer superior metabolic effects. However, comparative real-world cardiovascular outcomes in HFpEF patients remain understudied. Methods: We conducted a retrospective cohort study using the TriNetX Research Network. Adults with a diagnosis of HFpEF and obesity who were treated with either semaglutide or tirzepatide were identified.The primary outcome was all-cause mortality. Secondary outcomes included myocardial infarction (MI), stroke, cholelithiasis, and pancreatitis. Propensity score matching (1:1) was performed for age, sex, race, comorbidities, and baseline medications Results: After matching, 40,047 patients were included (Semaglutide: 20,028; Tirzepatide: 20,019). All-cause mortality was higher with Semaglutide (2.9% vs 2.0%; OR 1.47, 95% CI 1.29–1.67, p<0.001). Myocardial infarction occurred in 2.8% of Semaglutide users vs 2.2% with Tirzepatide (OR 1.28, p=0.001), while heart failure exacerbations were more frequent with Semaglutide (10.1% vs 8.3%; OR 1.24, p=0.012). Acute kidney injury was also slightly higher in the Semaglutide group (7.0% vs 6.2%; OR 1.14, p=0.016), as were readmissions (13.1% vs 10.2%; OR 1.33, p<0.001). Rates of cholelithiasis (1.7% vs 1.5%) and pancreatitis (0.4% vs 0.4%) were comparable. Kaplan-Meier survival analysis demonstrated significantly better survival with Tirzepatide (85.8% vs 74.7%, p<0.001), with a corresponding hazard ratio of 1.28 (95% CI 1.12–1.45), favoring Tirzepatide. Conclusions: In this large real-world cohort of obese patients with HFpEF, Tirzepatide was associated with lower risks of all-cause mortality, cardiovascular events, HF exacerbation, and readmissions compared to Semaglutide, without a significant increase in adverse events. These findings support the potential cardioprotective role of Tirzepatide and warrant prospective validation in HFpEF populations.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美幻桃完成签到,获得积分10
刚刚
俏皮诺言完成签到,获得积分10
1秒前
mdJdm完成签到 ,获得积分10
2秒前
123完成签到,获得积分10
5秒前
学术文献互助完成签到,获得积分0
5秒前
乐人完成签到 ,获得积分10
8秒前
佳佳完成签到 ,获得积分10
9秒前
pingbaby完成签到 ,获得积分10
9秒前
Sophia完成签到 ,获得积分10
10秒前
易道聚焦完成签到,获得积分10
12秒前
折耳根拌香菜完成签到 ,获得积分10
16秒前
linn1完成签到 ,获得积分10
17秒前
科研一坤年完成签到,获得积分10
17秒前
豆丁小猫完成签到,获得积分10
18秒前
万历十五年完成签到,获得积分10
18秒前
老辈子莫搞完成签到,获得积分10
19秒前
顺利的雨竹完成签到,获得积分10
22秒前
xiaxia42完成签到 ,获得积分0
24秒前
Ya完成签到 ,获得积分10
24秒前
Waboss完成签到,获得积分10
25秒前
25秒前
zcd完成签到 ,获得积分10
26秒前
日暮里123完成签到 ,获得积分10
26秒前
寻遇完成签到,获得积分10
27秒前
gdgd完成签到,获得积分10
27秒前
爱撒娇的蝴蝶完成签到 ,获得积分10
28秒前
28秒前
快乐雁风完成签到 ,获得积分10
29秒前
温暖冬日完成签到,获得积分10
30秒前
lxxxx完成签到 ,获得积分10
31秒前
假装超人会飞完成签到,获得积分10
31秒前
房杨发布了新的文献求助10
33秒前
eagletyr完成签到 ,获得积分10
34秒前
酸色黑樱桃完成签到,获得积分10
34秒前
hosanna完成签到 ,获得积分10
35秒前
优美的镜完成签到,获得积分10
35秒前
汪琪琪儿完成签到,获得积分10
35秒前
BBo完成签到 ,获得积分10
36秒前
汤汤完成签到 ,获得积分10
36秒前
粗犷的月饼完成签到 ,获得积分10
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180097
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808841
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479013